BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 34177786)

  • 1. Dominant Optic Atrophy (DOA): Modeling the Kaleidoscopic Roles of OPA1 in Mitochondrial Homeostasis.
    Del Dotto V; Carelli V
    Front Neurol; 2021; 12():681326. PubMed ID: 34177786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Establishing induced pluripotent stem cell lines from two dominant optic atrophy patients with distinct
    Pohl KA; Zhang X; Pham AH; Chan JW; Sadun AA; Yang XJ
    Front Genet; 2023; 14():1251216. PubMed ID: 37745862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CRISPR-Cas9 correction of
    Sladen PE; Perdigão PRL; Salsbury G; Novoselova T; van der Spuy J; Chapple JP; Yu-Wai-Man P; Cheetham ME
    Mol Ther Nucleic Acids; 2021 Dec; 26():432-443. PubMed ID: 34589289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimized OPA1 Isoforms 1 and 7 Provide Therapeutic Benefit in Models of Mitochondrial Dysfunction.
    Maloney DM; Chadderton N; Millington-Ward S; Palfi A; Shortall C; O'Byrne JJ; Cassidy L; Keegan D; Humphries P; Kenna P; Farrar GJ
    Front Neurosci; 2020; 14():571479. PubMed ID: 33324145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. OPA1: How much do we know to approach therapy?
    Del Dotto V; Fogazza M; Lenaers G; Rugolo M; Carelli V; Zanna C
    Pharmacol Res; 2018 May; 131():199-210. PubMed ID: 29454676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. OPA1 gene therapy prevents retinal ganglion cell loss in a Dominant Optic Atrophy mouse model.
    Sarzi E; Seveno M; Piro-Mégy C; Elzière L; Quilès M; Péquignot M; Müller A; Hamel CP; Lenaers G; Delettre C
    Sci Rep; 2018 Feb; 8(1):2468. PubMed ID: 29410463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. OPA1 functions in mitochondria and dysfunctions in optic nerve.
    Lenaers G; Reynier P; Elachouri G; Soukkarieh C; Olichon A; Belenguer P; Baricault L; Ducommun B; Hamel C; Delettre C
    Int J Biochem Cell Biol; 2009 Oct; 41(10):1866-74. PubMed ID: 19389483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dominant optic atrophy: updates on the pathophysiology and clinical manifestations of the optic atrophy 1 mutation.
    Chun BY; Rizzo JF
    Curr Opin Ophthalmol; 2016 Nov; 27(6):475-480. PubMed ID: 27585216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. OPA1 expression in the normal rat retina and optic nerve.
    Ju WK; Misaka T; Kushnareva Y; Nakagomi S; Agarwal N; Kubo Y; Lipton SA; Bossy-Wetzel E
    J Comp Neurol; 2005 Jul; 488(1):1-10. PubMed ID: 15912498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. OPA1 (Kjer type) dominant optic atrophy: a novel mitochondrial disease.
    Delettre C; Lenaers G; Pelloquin L; Belenguer P; Hamel CP
    Mol Genet Metab; 2002 Feb; 75(2):97-107. PubMed ID: 11855928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutations in DNM1L, as in OPA1, result in dominant optic atrophy despite opposite effects on mitochondrial fusion and fission.
    Gerber S; Charif M; Chevrollier A; Chaumette T; Angebault C; Kane MS; Paris A; Alban J; Quiles M; Delettre C; Bonneau D; Procaccio V; Amati-Bonneau P; Reynier P; Leruez S; Calmon R; Boddaert N; Funalot B; Rio M; Bouccara D; Meunier I; Sesaki H; Kaplan J; Hamel CP; Rozet JM; Lenaers G
    Brain; 2017 Oct; 140(10):2586-2596. PubMed ID: 28969390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. OPA1 haploinsufficiency induces a BNIP3-dependent decrease in mitophagy in neurons: relevance to Dominant Optic Atrophy.
    Moulis MF; Millet AM; Daloyau M; Miquel MC; Ronsin B; Wissinger B; Arnauné-Pelloquin L; Belenguer P
    J Neurochem; 2017 Feb; 140(3):485-494. PubMed ID: 27861891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. OPA1-related disorders: Diversity of clinical expression, modes of inheritance and pathophysiology.
    Chao de la Barca JM; Prunier-Mirebeau D; Amati-Bonneau P; Ferré M; Sarzi E; Bris C; Leruez S; Chevrollier A; Desquiret-Dumas V; Gueguen N; Verny C; Hamel C; Miléa D; Procaccio V; Bonneau D; Lenaers G; Reynier P
    Neurobiol Dis; 2016 Jun; 90():20-6. PubMed ID: 26311407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deciphering OPA1 mutations pathogenicity by combined analysis of human, mouse and yeast cell models.
    Del Dotto V; Fogazza M; Musiani F; Maresca A; Aleo SJ; Caporali L; La Morgia C; Nolli C; Lodi T; Goffrini P; Chan D; Carelli V; Rugolo M; Baruffini E; Zanna C
    Biochim Biophys Acta Mol Basis Dis; 2018 Oct; 1864(10):3496-3514. PubMed ID: 30293569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early-onset severe neuromuscular phenotype associated with compound heterozygosity for OPA1 mutations.
    Schaaf CP; Blazo M; Lewis RA; Tonini RE; Takei H; Wang J; Wong LJ; Scaglia F
    Mol Genet Metab; 2011 Aug; 103(4):383-7. PubMed ID: 21636302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. OPA1-associated disorders: phenotypes and pathophysiology.
    Amati-Bonneau P; Milea D; Bonneau D; Chevrollier A; Ferré M; Guillet V; Gueguen N; Loiseau D; de Crescenzo MA; Verny C; Procaccio V; Lenaers G; Reynier P
    Int J Biochem Cell Biol; 2009 Oct; 41(10):1855-65. PubMed ID: 19389487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased steroidogenesis promotes early-onset and severe vision loss in females with OPA1 dominant optic atrophy.
    Sarzi E; Seveno M; Angebault C; Milea D; Rönnbäck C; Quilès M; Adrian M; Grenier J; Caignard A; Lacroux A; Lavergne C; Reynier P; Larsen M; Hamel CP; Delettre C; Lenaers G; Müller A
    Hum Mol Genet; 2016 Jun; 25(12):2539-2551. PubMed ID: 27260406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of a MGM1/OPA1 chimeric gene for functional analysis in yeast of mutations associated with dominant optic atrophy.
    Nolli C; Goffrini P; Lazzaretti M; Zanna C; Vitale R; Lodi T; Baruffini E
    Mitochondrion; 2015 Nov; 25():38-48. PubMed ID: 26455272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of opa1 isoforms expression and apoptosis regulation in autosomal dominant optic atrophy (ADOA) patients with mutations in the opa1 gene.
    Formichi P; Radi E; Giorgi E; Gallus GN; Brunetti J; Battisti C; Rufa A; Dotti MT; Franceschini R; Bracci L; Federico A
    J Neurol Sci; 2015 Apr; 351(1-2):99-108. PubMed ID: 25796301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modeling autosomal dominant optic atrophy using induced pluripotent stem cells and identifying potential therapeutic targets.
    Chen J; Riazifar H; Guan MX; Huang T
    Stem Cell Res Ther; 2016 Jan; 7():2. PubMed ID: 26738566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.